ACAD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACAD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-19), ACADIA Pharmaceuticals's share price is $17.125. ACADIA Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $2.62. Hence, ACADIA Pharmaceuticals's PB Ratio of today is 6.53.
Good Sign:
ACADIA Pharmaceuticals Inc stock PB Ratio (=6.51) is close to 1-year low of 6.51
The historical rank and industry rank for ACADIA Pharmaceuticals's PB Ratio or its related term are showing as below:
During the past 13 years, ACADIA Pharmaceuticals's highest PB Ratio was 17.81. The lowest was 4.54. And the median was 9.06.
During the past 12 months, ACADIA Pharmaceuticals's average Book Value Per Share Growth Rate was 6.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -12.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -8.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 2.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ACADIA Pharmaceuticals was 91.30% per year. The lowest was -48.00% per year. And the median was 7.60% per year.
The historical data trend for ACADIA Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ACADIA Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ACADIA Pharmaceuticals's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Dec. 2023) |
= | 17.125 | / | 2.622 | |
= | 6.53 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ACADIA Pharmaceuticals (NAS:ACAD) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Austin D. Kim | officer: EVP & General Counsel | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Brendan Teehan | officer: EVP, COO, Head of Commercial | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Stephen Davis | director, officer: PRESIDENT AND CEO | ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
James Kihara | officer: Principal Accounting Officer | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Mark C. Schneyer | officer: Chief Financial Officer | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Laura Brege | director | C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608 |
Baker Bros. Advisors Lp | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Douglas J Williamson | officer: Executive VP, Research & Dev | AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390 |
Srdjan R. Stankovic | officer: EVP | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Adora Ndu | director | C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120 |
Elena Ridloff | officer: EVP and CFO | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Michael J. Yang | officer: EVP AND CCO | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Elizabeth A. Garofalo | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
James M Daly | director | INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880 |
Eric Alejandro Miller | officer: Controller & PAO | C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
From GuruFocus
By Business Wire • 01-18-2024
By Business Wire • 12-21-2023
By Business Wire • 07-13-2023
By Business Wire • 12-14-2023
By Business Wire • 12-18-2023
By Business Wire • 07-24-2023
By Business Wire • 10-19-2023
By Business Wire • 11-27-2023
By Business Wire • 06-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.